FDA OKs Pfizer’s Lipitor for use in diabetics
CHICAGO (Reuters) – Pfizer Inc. said on Tuesday U.S.
regulators have approved its blockbuster cholesterol drug
Lipitor to reduce the risk of stroke and heart attack in
Pfizer said the approval is for patients with type 2, or
adult onset, diabetes who have no signs of heart disease but
with other risk factors for the condition.
Pfizer said Lipitor also received approval to reduce the
risk of stroke in people without evidence of heart disease but
with multiple risk factors other than diabetes.
Common risk factors include high cholesterol, high blood
pressure, a family history of heart disease, smoking and
With the approvals, even diabetic patients with normal
levels of LDL or “bad” cholesterol need only one other risk
factor for heart disease, such as high blood pressure, to
benefit from the drug, Pfizer said.
The approvals were based on two large studies showing the
drug reduced the risk of heart attack and stroke in diabetic
More than 18 million Americans have diabetes, which is a
leading risk factor for cardiovascular disease.
Medical experts estimate that between one-quarter and
one-third of diabetics have symptoms of cardiovascular disease
and patients with diabetes have a much higher risk of dying
from heart disease than other people.
Shares of Pfizer rose 1 cent to $25.20 in Tuesday morning
trade on the New York Stock Exchange.